26 participants
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2017-11-30
- Start Date:
- 2014-07-31
- Completion:
- 2015-05-31
Conditions
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Myelodysplastic Syndrome (MDS)
Interventions
- DRUG